Stock 9688 ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Zai Lab Limited Stock Hong Kong S.E.

Equities

9688

KYG9887T1168

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
12.64 HKD +2.10% Intraday chart for Zai Lab Limited +19.02% -41.21%
Apr. 17 Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading MT
Apr. 11 Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT

Financials

Sales 2024 * 379M 2.97B Sales 2025 * 635M 4.97B Capitalization 1.55B 12.1B
Net income 2024 * -317M -2.48B Net income 2025 * -126M -986M EV / Sales 2024 * 2.78 x
Net cash position 2024 * 491M 3.84B Net cash position 2025 * 275M 2.15B EV / Sales 2025 * 2 x
P/E ratio 2024 *
-4.79 x
P/E ratio 2025 *
-15.2 x
Employees 2,175
Yield 2024 *
-
Yield 2025 *
1.28%
Free-Float 89.99%
More Fundamentals * Assessed data

Chart Zai Lab Limited

Dynamic Chart

Latest news about Zai Lab Limited

Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading MT
Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT
Zai Lab Changes Record Date MT
Zai Lab Grants Share Options, Restricted Share Units to Eligible Personnel MT
Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint MT
Zai Lab Reports Lesser Loss in 2023 MT
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients MT
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer CI
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading MT
Asian Equities Traded in the US as American Depositary Receipts End Week Lower in Friday Trading MT
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate for Treatment of Solid Tumors CI
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading MT
Transcript : Zai Lab Limited, 2023 Earnings Call, Feb 28, 2024
Zai Lab's Loss Narrows in 2023 MT
Earnings Flash (ZLAB) ZAI LAB LIMITED Reports 2023 Revenue $266.7M MT
More news

Latest transcript on Zai Lab Limited

Logo Zai Lab Limited
Zai Lab Limited, 2023 Earnings Call, Feb 28, 2024
More transcripts

Analyst Recommendations on Zai Lab Limited

Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT
Zai Lab Grants Share Options, Restricted Share Units to Eligible Personnel MT
Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target MT
Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating MT
Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating MT
More recommendations

Press releases Zai Lab Limited

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024 BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities AQ
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs BU
More press releases

News in other languages on Zai Lab Limited

Hong Kong se convierte en el principal mercado para las cotizaciones chinas, según HKEX -- Market Talk
Tweede kwartaal Argen-x in teken lancering Vyvgart
Brussel fors hoger van start na Fed-rally op Wall Street
Argenx boekt eerste omzet met Vyvgart
EN DIRECTO DESDE LOS MERCADOS: Stellantis, Wendel, Soitec, Umanis, Tod's, Deutsche Telekom, Oracle, Rivian...
More news

Quotes and Performance

1 day+2.10%
1 week+19.02%
Current month-2.02%
1 month+0.48%
3 months-29.07%
6 months-35.64%
Current year-41.21%
More quotes

Highs and lows

1 week
10.56
Extreme 10.56
12.74
1 month
10.56
Extreme 10.56
13.18
Current year
10.56
Extreme 10.56
21.65
1 year
10.56
Extreme 10.56
29.50
3 years
10.56
Extreme 10.56
142.00
5 years
10.56
Extreme 10.56
151.20
10 years
10.56
Extreme 10.56
151.20
More quotes

Managers and Directors - Zai Lab Limited

Managers TitleAgeSince
Ying Du CEO
 Chief Executive Officer 59 14-03-31
Ya jing Chen DFI
 Director of Finance/CFO 56 21-08-31
Joshua Smiley PSD
 President 54 22-07-31
Members of the board TitleAgeSince
John D. Diekman BRD
 Director/Board Member 81 16-12-31
Peter Wirth BRD
 Director/Board Member 73 16-12-31
Lonnie Moulder BRD
 Director/Board Member 66 18-12-31
More insiders

ETFs positioned on Zai Lab Limited

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI CHINA ESG LEADERS ETF - USD ETF KraneShares MSCI China ESG Leaders ETF - USD
0.31% 4 M€ -11.56%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.28% 2 M€ -14.14%
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR
0.04% 2,808 M€ +4.61% -
More ETFs positioned on Zai Lab Limited

Quotes

Date Price Change Volume
24-04-25 12.64 +2.10% 5 020 250
24-04-24 12.38 +2.48% 4,733,296
24-04-23 12.08 +5.59% 5,466,955
24-04-22 11.44 +6.12% 5,379,678
24-04-19 10.78 +1.51% 5,002,013

Delayed Quote Hong Kong S.E., April 25, 2024 at 04:09 am EDT

More quotes

Company Profile

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
2024-05-07 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Zai Lab Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.66 USD
Average target price
52.5 USD
Spread / Average Target
+235.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 40.86B
BIOGEN INC. Stock Biogen Inc.
-21.94% 29.36B
UCB Stock UCB
+55.77% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.26B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.31B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+8.31% 8.31B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. 9688 Stock